FDA Drug Safety Communication: Ongoing Safety Review of GnRH Agonists and possible increased risk of diabetes and certai
This is a discussion on FDA Drug Safety Communication: Ongoing Safety Review of GnRH Agonists and possible increased risk of diabetes and certai within the FDA News forum, part of the Industry News and Updates category; The U.S. Food and Drug Administration (FDA) is evaluating whether Gonadotropin-Releasing Hormone (GnRH) Agonists may increase the risk ...
|
|||||||
| Register | Help | Members List | Mark Forums Read |
05-03-2010, 02:46 PM
|
|||
|
|||
FDA Drug Safety Communication: Ongoing Safety Review of GnRH Agonists and possible increased risk of diabetes and certai
The U.S. Food and Drug Administration (FDA) is evaluating whether Gonadotropin-Releasing Hormone (GnRH) Agonists may increase the risk of diabetes and certain cardiovascular diseases (heart attack, sudden cardiac death, stroke) in men receiving these medications for the treatment of prostate cancer.
More... 
|
 |
«
Previous Thread
|
Next Thread
»
| Thread Tools | |
| Display Modes | |
Linear Mode
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| FDA Drug Safety Communication: Ongoing Safety Review of Stalevo (entacapone/carbidopa/levodopa) and possible development | industry_news | FDA News | 0 | 03-31-2010 02:28 PM |
| FDA Drug Safety Communication: Ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fracture | industry_news | FDA News | 0 | 03-10-2010 03:42 PM |
| FDA Drug Safety Communication: Ongoing safety review of Invirase (saquinavir) and possible association with abnormal hea | industry_news | FDA News | 0 | 02-23-2010 12:59 PM |
| FDA updates the Early Communication about the Ongoing Safety Review of Bisphosphonates | industry_news | FDA News | 0 | 11-12-2008 11:48 AM |
| Epoetin alfa - Early Communication about an Ongoing Safety Review | industry_news | FDA News | 0 | 09-26-2008 12:42 PM |
© 2008 DrugManagementForum™ powered by |
 |